Clinician – NSCLC

Clinician Toolkit

Our goals are to provide information that supports open communication between patients and providers and to improve patient care.

HD Visual Learning

Dynamic HD animations about ROP
Interactive, downloadable learning tools for mobile devices

Introduction

Overview of NSCLC

Rationale for Immunotherapy in NSCLC

Explore the immunopathologic factors in the pathogenesis of NSCLC

Biomarker-Directed Use of Immune Checkpoint Inhibitors for NSCLC

Review strategies for targeting NSCLC based on appropriate application of clinical biomarkers

Clinical trials for first-line therapies in NSCLC

Up-to-date clinical trial data concerning front-line use of immuno-oncology strategies in NSCLC

Reading and Resources

Links to further education and resources

This activity is provided by Med Learning Group.
This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Scientific Council

Did you come from ENCOMPASS?

View more tumor types at encompass-cancer.com

Search

[divi_global_search_form]

Clinician Scientific & Educational Resources

The RELIEF Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for retinopathy of prematurity (ROP). Click on one of the options below to learn more about ROP.

HD Visual Learning

Dynamic HD animations about ROP
Interactive, downloadable learning tools for mobile devices

Patient Toolkit

What exactly is NSCLC?

What symptoms can NSCLC cause?

How is NSCLC treated according to staging?

How is early NSCLC treated with surgery or SBRT?

When is chemotherapy used in NSCLC?

When is radiation used in NSCLC?

When is immunotherapy used in NSCLC?

When is targeted therapy used in NSCLC?

Patient Journey

Online resources

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM). This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

NSCLC Initiative

Clinician Toolkit

HD Visual Learning

Introduction

Introduction

Rationale for Immunotherapy in NSCLC

Rationale for Immunotherapy in NSCLC

Biomarker-Directed Use of Immune Checkpoint Inhibitors for NSCLC

Biomarker-Directed Use of Immune Checkpoint Inhibitors for NSCLC

Clinical trials for first-line therapies in NSCLC

Clinical trials for first-line therapies in NSCLC

Reading and Resources

Reading and Resources

Scientific Council

Neil M. Bressler, MD

A. Paul Chous, MA, OD, FAAO

Steven Ferrucci, OD, FAAO

Julia A. Haller, MD

Allen C. Ho, MD, FACS

Charles C. Wykoff, MD, PhD

Did you come from ENCOMPASS?

View more tumor types at encompass-cancer.com

Search

Español

Retinopathy of Prematurity

Español

Clinician Scientific & Educational Resources

HD Visual Learning

Patient Toolkit

Patient Toolkit

What exactly is NSCLC?

What exactly is NSCLC?

What symptoms can NSCLC cause?

What symptoms can NSCLC cause?

How is NSCLC treated according to staging?

How is NSCLC treated according to staging?

How is early NSCLC treated with surgery or SBRT?

How is early NSCLC treated with surgery or SBRT?

When is chemotherapy used in NSCLC?

When is chemotherapy used in NSCLC?

When is radiation used in NSCLC?

When is radiation used in NSCLC?

When is immunotherapy used in NSCLC?

When is immunotherapy used in NSCLC?

When is targeted therapy used in NSCLC?

When is targeted therapy used in NSCLC?

Patient Journey

Patient Journey

Online resources

Online resources